Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation

Seminars in Thrombosis and Hemostasis

Volumn 27, Issue 6, 2001, Pages 657-666

  Horan, J T ^a   Francis, C W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

D dimer; DIC; Disseminated intravascular coagulation; Endotoxin; Fibrin(ogen) degradation products; Soluble fibrin

Indexed keywords

D DIMER; ENDOTOXIN; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRIN MONOMER; FIBRINOGEN; FIBRINOPEPTIDE; PLASMIN; THROMBIN;

ARTICLE; BIOASSAY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISSEMINATED INTRAVASCULAR CLOTTING; EXPERIMENTAL MODEL; FIBRIN FORMATION; FIBRIN POLYMERIZATION; FIBRINOLYSIS; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; SCORING SYSTEM; STANDARDIZATION;

ANIMALS; BIOLOGICAL ASSAY; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; PREDICTIVE VALUE OF TESTS;

EID: 0035217849     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18870     Document Type: Article

References (58)

1. Soluble complex of fibrinogen and fibrin
2. Incorporation of fibrinogen into soluble fibrin complexes
3. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting
4. Some aspects of the bonds interlinking soluble fibrin complexes in human plasma
5. Occurrence of soluble very-high-molecular-weight fibrinogen complexes in hypercoagulable states. An in vitro and in vivo study on their features
6. Increased plasma concentration of crosslinked fibrin polymers in acute myocardial infarction
7. Normal and fibrinaemic patient plasma contain high-molecular-weight crosslinked fibrin(ogen) derivatives with intact fibrinopeptide A
8. Data for defining fibrinogen and its plasmic degradation products
9. Plasmic degradation of crosslinked fibrin: Characterization of new macromolecular soluble complexes and a model of their structure
10. A molecular model of plasmic degradation of crosslinked fibrin
11. Subunit structure of fragment D from fibrinogen and cross-linked fibrin
12. Subunit structure of the plasmin-induced degradation products of crosslinked fibrin
13. Characterization of a soluble D-dimer-E complex in crosslinked fibrin digests
14. Fibrin and fibrinogen proteolysis products: Comparison between gel filtration and SDS polyacrylamide electrophoresis analysis
15. Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular soluble complexes
16. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation
17. Subunit and macromolecular structure of circulating fibrin from obstetric patients with intravascular coagulation
18. Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique
19. Specific identification of fibrin(ogen) degradation products in plasma and serum using blotting and peroxidase labeled antiserum
20. Fibrinogen Aα and γ-chain dimers as potential differential indicators of atherosclerotic and thrombotic vascular disease
21. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A
22. Normal and fibrinaemic patient plasma contain high-molecular weight crosslinked fibrin(ogen) derivatives with intact fibrinopeptide A
23. Studies on soluble fibrin in plasma. II. N-terminal analysis of a modified fraction 1 (Cohn) from patient plasmas
24. Laboratory identification of intravascular coagulation: The serial dilution protamine sulfate test for the detection of fibrin monomer and fibrin degradation products
25. Gelation of soluble fibrin in plasma by ethanol
26. Affinity chromatography and quantitation of soluble fibrin from plasma
27. Fibrin polymerization and release of fibrinopeptide B by thrombin
28. Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin
29. The sequence γ-(312-324) is a fibrin-specific epitope
30. A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexes with fibrinogen or its derivatives: Its application to the measurement of soluble fibrin in plasma
31. Thrombus precursor protein (TpP): Marker of thrombosis early in the pathogenesis of myocardial infarction
32. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay
33. Comparison of methods for detecting soluble fibrin in plasma, an in vitro study
34. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy
35. The role of soluble crosslinked fibrin in D-dimer immunoreactivity of plasmic digests
36. A soluble fibrin standard: Comparable dose-response with immunologic and functional assays
37. Prevalence and clinical implications of heparin-associated false-positive tests for serum fibrin(ogen) degradation products
38. Application of a novel and rapid whole blood assay for D-dimer in patients with clinically suspected pulmonary embolism
39. Effect of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats
40. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis
41. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation - Effect of interleukin-6
42. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
43. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia
44. Lepirudin blunts endotoxin-induced coagulation activation
45. Screening tests of disseminated intravascular coagulation: Guidelines for rapid and specific laboratory diagnosis
46. Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation
47. Diagnosis of disseminated intravascular coagulation. Role of D-dimer
48. Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC)
49. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation
50. The significance of fibrinogen derivatives in plasma in human renal failure
51. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease
52. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: An overview
53. D-dimer test and diagnosis of deep vein thrombosis: A comparative study of 7 assays
54. A comparative analysis of D-dimer assays in patients with clinically suspected pulmonary embolism
55. Fibrin degradation product (FnDP) assays: Analysis of standardization issues and target antigens in plasma
56. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies
57. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome
58. Hemostatic molecular markers before the onset of disseminated intravascular coagulation